Paulo Roberto Gomes Takey

Paulo Roberto Gomes Takey

Auto-generated profile, based on publicly available information

Paulo Roberto Gomes Takey

Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Institute of Technology in Immunobiologicals/Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
POPatricia Mouta Nunes de Oliveira
Patricia Mouta Nunes de Oliveira
LLLetícia Kegele Lignani
Letícia Kegele Lignani
DCDeborah Araújo da Conceição
Deborah Araújo da Conceição
PFPaula Molinari Cardoso de Mello Farias
Paula Molinari Cardoso de Mello Farias
PTPaulo Roberto Gomes Takey
Paulo Roberto Gomes Takey
LCLuiz Antonio Bastos Camacho
Luiz Antonio Bastos Camacho
A vacinação é uma das ações mais efetivas para proteger o indivíduo e a população contra doenças imunopreveníveis. Vacinas são produtos seguros e eficazes, porém, como qualquer outro medicamento, podem causar eventos adversos, que ganham maior visibilidade na medida em que as doenças são controladas, eliminadas ou erradicadas. Este trabalho analisou as ações de vigilância de eventos adversos pós-vacinação (EAPV) com base em dados da literatura científica e sites de programas de imunizações, agências reguladoras e de saúde, além da expertise dos autores nas áreas de imunizações e farmacovigilância. Com o aumento do número de vacinas no calendário básico e a ampliação do acesso da população, tornou-se fundamental o estabelecimento de um sistema eficiente de vigilância de EAPV no Brasil. Entretanto, a subnotificação de casos no Brasil e em outros países dificulta a detecção de EAPV, principalmente os raros. Informações sempre atualizadas sobre o benefício/risco das vacinas permitem que programas de imunizações deem respostas rápidas e claras aos rumores de EAPV. Isso garante a confiabilidade no sistema, ainda mais diante do crescente movimento antivacinista e a influência cada vez maior das mídias sociais na opinião pública.

31 October 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
DMDaniela Palheiro Mendes-de-Almeida
Daniela Palheiro Mendes-de-Almeida
AVAnna Paula Bise Viegas
Anna Paula Bise Viegas
LJLiliam Cristiana Júlio
Liliam Cristiana Júlio
ABAna Paula Pietrowski Bertuol
Ana Paula Pietrowski Bertuol
EFEder Gatti Fernandes
Eder Gatti Fernandes
MMMaria de Lourdes de Sousa Maia
Maria de Lourdes de Sousa Maia
The emergence of new variants of SARS-CoV-2 has led to the administration of different booster vaccines to mitigate COVID-19. Vaccines with adenoviral vectors have been rarely associated with vaccine-induced immune thrombotic thrombocytopenia (VITT). This study aimed to describe 15 cases of VITT after the third and fourth doses of the COVID-19 vaccine in Brazil. Cases were reported after all kinds of anti-SARS-CoV-2 booster vaccinations between October 17, 2021, and September 4, 2022. Of the 26 suspected cases, 15 cases of VITT were analyzed. Of these, 10 were classified as definite VITT, 2 as probable, 1 as possible, and 2 as unlikely. The estimated frequency of definite, probable, or possible VITT was 0.33 cases per million. Cases were assigned to ChAdOx1 (13 cases), Ad26.COV2.S (1 case), and BNT162b2 (1 case). None of the patients received an adenoviral vaccine as a primary vaccination. The average age of participants was 34 years, and symptoms usually appeared 8 days after vaccination. Headache was the most common symptom, and cerebral veins were the most affected thrombotic site. The overall mortality risk was 53%. Anti-platelet factor 4 enzyme-linked immunosorbent assay serology was positive in 11 out of 15 patients (73.3%), negative in 2 (13.3%), and missing in 2 (13.3%). The study confirms that VITT is linked to the first exposure to adenoviral vector vaccines. Since January 2023, Brazil has recommended preferably COVID-19 messenger RNA vaccines for individuals aged 18 to 39 years. We suggest that, in the current disease scenario, COVID-19 adenovirus vaccines should not be the first choice for individuals aged <50 years who have not received a previous dose of this type of vaccine.

1 January 2022
Verified
Conference Paper
Open access
PDF file
GTGabriellen Vitiello Teixeira
Gabriellen Vitiello Teixeira
RPRenata Saraiva Pedro
Renata Saraiva Pedro
LLLetícia Kegele Lignani
Letícia Kegele Lignani
CCCatherine Crespo Cordeiro
Catherine Crespo Cordeiro
POPatrícia Oliveira
Patrícia Oliveira
PTPaulo Takey
Paulo Takey